1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Ergot Alkaloids (Migraine) - Forecast and Market Analysis to 2023

Ergot Alkaloids (Migraine) - Forecast and Market Analysis to 2023

  • March 2014
  • -
  • GlobalData
  • -
  • 47 pages

Summary

Table of Contents

Ergot Alkaloids (Migraine) - Forecast and Market Analysis to 2023

Summary

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

The Ergot Alkaloids were the very first anti-migraine-specific therapy class to reach the market. The first pure ergot alkaloid was isolated in 1920, but only in 1925 was ergotamine used to successfully treat a case of severe and intractable migraine via subcutaneous injection (Rothlin, 1955; Stoll, 1965). Over the following decades, ergotamine’s use as a migraine treatment was investigated by various researchers and its potent vasoconstriction properties reinforced the belief that migraine had a vascular origin.

Scope

- Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Ergot Alkaloids including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Ergot Alkaloids for the top two countries from 2012 to 2023.
- Sales information covered for the US and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Migraine
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Ergot Alkaloids performance
- Obtain sales forecast for Ergot Alkaloids from 2012-2023 in the top two countries (the US and Japan)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Sumatriptan Sales, Price Analysis, & Sales Forecast - 2017

Sumatriptan Sales, Price Analysis, & Sales Forecast - 2017

  • $ 1100
  • Industry report
  • April 2017
  • by Fore Pharma

Fore Pharma has released its new research, Sumatriptan Sales, Price Analysis, & Sales Forecast – 2017. Find out the sales of Sumatriptan worldwide and by countries in North America, Europe, Japan, BRIC, ...

Rizatriptan Sales, Price Analysis, & Sales Forecast - 2017

Rizatriptan Sales, Price Analysis, & Sales Forecast - 2017

  • $ 1100
  • Industry report
  • April 2017
  • by Fore Pharma

Fore Pharma has released its new research, Rizatriptan Sales, Price Analysis, & Sales Forecast – 2017. Find out the sales of Rizatriptan worldwide and by countries in North America, Europe, Japan, BRIC, ...

Frovatriptan Sales, Price Analysis, & Sales Forecast - 2017

Frovatriptan Sales, Price Analysis, & Sales Forecast - 2017

  • $ 1100
  • Industry report
  • April 2017
  • by Fore Pharma

Fore Pharma has released its new research, Frovatriptan Sales, Price Analysis, & Sales Forecast – 2017. Find out the sales of Frovatriptan worldwide and by countries in North America, Europe, Japan, ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the US

  • April 2017
    44 pages
  • Therapy  

    Serotonin Speci...  

    Antidepressant  

  • United States  

View report >

Therapy Market in the US

  • March 2017
    253 pages
  • Therapy  

    Anti-Infective  

    Hormone  

  • United States  

View report >

Therapy Market in the US

  • March 2017
    253 pages
  • Therapy  

    Anti-Infective  

    Hormone  

  • United States  

View report >

Therapy Market

4 months ago

Related Market Segments :

Antimigraine
Therapy
Pain Relief

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.